Company news

Natera, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Natera to Report Its Second Quarter Results on August 7, 2025

July 30, 2025

Natera Announces Launch of ABCSG 61 ("TEODOR"), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer

July 29, 2025

PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT

July 23, 2025

Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer

July 6, 2025

Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD

June 30, 2025

Natera Announces Medicare Coverage for Signatera™ Genome

June 3, 2025

SignateraTM Genome Clinical Performance Highlighted at ASCO 2025

June 1, 2025

Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting

May 21, 2025

Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress

May 7, 2025

Natera Reports First Quarter 2025 Financial Results

May 7, 2025

Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows

May 6, 2025

Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera

May 4, 2025

Natera to Report its First Quarter Results on May 8, 2025

April 30, 2025

Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction

April 28, 2025

Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test

April 23, 2025

Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting

April 21, 2025

DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting

March 24, 2025

Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer

March 9, 2025

Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD

March 3, 2025

Natera Reports Fourth Quarter and Full Year 2024 Financial Results

February 26, 2025

Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer

February 24, 2025

Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025

February 17, 2025

NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma

February 9, 2025

Natera Announces National Commercial Coverage for its Fetal RhD NIPT

February 2, 2025

Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer

January 24, 2025

Natera to Present New Data at the 2025 ASCO GI Symposium

January 20, 2025

Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year

January 16, 2025

Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection

January 14, 2025

Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024

January 11, 2025

Natera to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

January 6, 2025

Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics

December 16, 2024

Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer

December 11, 2024

Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment

December 8, 2024

Clinical Validation Study on Natera’s Fetal RhD NIPT Published in Obstetrics & Gynecology

December 1, 2024

Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients

November 26, 2024

Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium

November 24, 2024

Natera Issues Statement on Guardant Health Litigation

November 24, 2024

Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the Year

November 24, 2024

Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM

November 20, 2024

Natera Reports Third Quarter 2024 Financial Results

November 11, 2024

Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer

November 11, 2024

Natera to Participate in Upcoming Investor Conferences

November 7, 2024

Natera to Report its Third Quarter 2024 Results on November 12, 2024

October 31, 2024

Natera to Present New Renasight Data at ASN Kidney Week 2024

October 21, 2024

Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase

September 22, 2024

Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO

September 15, 2024

First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival

September 13, 2024

Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival

September 7, 2024

Natera to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

August 27, 2024

Natera Reports Second Quarter 2024 Financial Results

August 7, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 57 decks. Every deck is listed under its year.